Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial

Mulvenna, P.; Nankivell, Matthew; Barton, Rachael; Faivre‐Finn, Corinne; Wilson, Paula; McColl, Elaine; Moore, Barbara; Brisbane, I.; Ardron, David; Holt, Tanya; Morgan, Sally; Lee, Caroline; Waite, Kathryn; Bayman, N.; Pugh, Cheryl; Sydes, Benjamin; Stephens, Richard; Parmar, Mahesh; E. Langley, Ruth

doi:10.1016/s0140-6736(16)30825-x

Public

Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial

Published in The Lancet • Sep 7, 2016

Authors:

P. Mulvenna

Matthew Nankivell

Rachael Barton

Abstract

BACKGROUND: Whole brain radiotherapy (WBRT) and dexamethasone are widely used to treat brain metastases from non-small cell lung cancer (NSCLC), although there have been no randomised clinical trials showing that WBRT improves either quality of life or overall survival. Even after treatment with WBR...

Subject

Medicine

Dexamethasone

Quality of life (healthcare)

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!